Home
Approach
Product
About
News
Contact
News
Login
Altis in the
news
.
Follow our journey to improving patient outcomes.
Filter
All
Announcements
Publications
Media Coverage
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
Axios: Clinical trial startup seeds $6M to speed research
Axios: Clinical trial startup seeds $6M to speed research
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
Next
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
Altis Labs leads initiative leveraging artificial intelligence to improve ICU care
Former AstraZeneca R&D Chief Information Officer John Conway joins Altis Labs as a Senior Advisor
Altis Labs announces launch of Nota – a clinical information platform to accelerate therapeutic R&D
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
Automated imaging-based stratification of early-stage lung cancer patients using deep learning applied to pretreatment CT scans
Deep learning applied to pretreatment CTs provides personalized prognostic insight for lung cancer patients
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
Axios: Clinical trial startup seeds $6M to speed research
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI